Showing 4341-4350 of 7009 results for "".
- Advancements in Predicting Postoperative Reintubation Riskhttps://reachmd.com/news/advancements-in-predicting-postoperative-reintubation-risk/2484639/A new point-based risk score identifies patients at elevated risk of reintubation within 24 hours and reduces unrecognized events—its discrimination (AUROC 0.831) supports targeted postoperative and ED surveillance. Age <1 or >65 years, ASA classification ≥III,
- The Emerging Impact of Digital Habits on Mental Health: A Clinical Perspectivehttps://reachmd.com/news/the-emerging-impact-of-digital-habits-on-mental-health-a-clinical-perspective/2484649/A one-week, structured reduction in social media use produced measurable short‑term improvements in young adults’ mental health. The study fou
- Advancements in AI-Driven Breast Cancer Risk Stratificationhttps://reachmd.com/news/advancements-in-ai-driven-breast-cancer-risk-stratification/2484658/At a RSNA presentation, an image-only AI model showed stronger five‑year breast cancer risk stratification than breast
- Phase II DAHLIAS Trial: Nipocalimab's Impact on Sjögren Diseasehttps://reachmd.com/news/phase-ii-dahlias-trial-nipocalimabs-impact-on-sjogren-disease/2484633/The DAHLIAS trial notes clinically meaningful reductions in disease activity with nipocalimab and supports FcRn blockade as the mechanistic rationale for antibody lowering. The authors
- AI Model Accurately Scores Psoriasis Severity from Clinical Imageshttps://reachmd.com/news/ai-model-accurately-scores-psoriasis-severity-from-clinical-images/2484588/A new study demonstrates the potential of artificial intelligence (AI) to improve the consistency and objectivity of psoriasis severity assessments based on 2D clinical images. Researchers for the study used the YOLOv8 deep lear
- FDA's Regulatory Green Light for Gene-Editing Therapy in PH1 Spurs New Hope in Renal Disease Treatmenthttps://reachmd.com/news/fdas-regulatory-green-light-for-gene-editing-therapy-in-ph1-spurs-new-hope-in-renal-disease-treatment/2484579/The FDA has cleared the YOLT-203 pivotal trial, enabling a first‑in‑class in vivo gene‑editing pivotal study for Primary Hyperoxaluria Type 1 (PH1).
- Elective Front-of-neck Access in Pediatric Airway Emergencies: A Clinical Updatehttps://reachmd.com/news/elective-front-of-neck-access-in-pediatric-airway-emergencies-a-clinical-update/2484563/An 8-year-old underwent an elective front-of-neck access for an anticipated cannot-intubate–cannot-ventilate (CICO) scenario; the si
- Allergan Aesthetics Celebrates Seventh Annual BOTOX® Cosmetic Dayhttps://reachmd.com/news/allergan-aesthetics-celebrates-seventh-annual-botox-cosmetic-day/2484512/Allergan Aesthetics, an AbbVie company, marks the seventh annual BOTOX® Cosmetic Day on Wednesday, November 19, 2025. The yearly celebration honors patients and providers who have contributed to the longevity and success of the injectable treatment, which remains the top-selling product in its ca
- Root Canal Treatment: Linking Oral Health to Systemic Disease Managementhttps://reachmd.com/news/root-canal-treatment-linking-oral-health-to-systemic-disease-management/2484503/A prospective two‑year cohort study found that successful treatment of apical periodontitis via root canal treatment was associated with measurable
- Bariatric Surgery vs GLP-1 Receptor Agonists: A Comparative Analysis for Obesity Treatmenthttps://reachmd.com/news/bariatric-surgery-vs-glp-1-receptor-agonists-a-comparative-analysis-for-obesity-treatment/2484463/A two-year cohort analysis found that metabolic bariatric surgery delivered substantially greater mean weight loss and lower total costs over two